
Opinion|Videos|September 27, 2024
Frontline Treatment and Sequencing Therapy
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What does your institution use for frontline treatment and how do you sequence therapy for patients who are transplant-eligible?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
4
Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings
5













































































































































































































